A Study of HS-20110 in Participants with Advanced Solid Tumors
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Solid Tumors
DRUG: HS-20110 (Phase Iaï¼šDose escalation )|DRUG: HS-20110 (Phase Ib:Dose expansion )
Maximum tolerated dose (MTD) or maximum applicable dose (MAD), From day 1 to one months after the last dose in Phase 1a|Objective response rate (ORR) as per RECIST v1.1, From screening to 2 months after the last dose
Incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose modification or permanent discontinuation, and specific laboratory abnormalities, From the first dose until 90 days after the last dose|Objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; overall survival (OS), From screening to up to 3 years after last dose|Incidence of anti-HS-20110 antibody (ADA), From the first dose until 90 days after the last dose|Drug concentrations of the three components of HS-20110 (including antibody-drug conjugates, total antibody, and payload), From the first dose until 90 days after the last dose
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors